Melanotan-1 · Research brief

Melanotan-1 for Sunless Tanning — Real Peptides

Real Peptides Research TeamEditorial

Updated March 26, 202612 min read

41 WORDS

Short answer

Key takeaways

Melanotan-1 activates the MC1R receptor on melanocytes, triggering the same CREB-MITF-tyrosinase pathway that UV radiation initiates, producing eumelanin without DNA photoproducts.
Clinical trials in EPP patients demonstrated 3–4 Fitzpatrick scale increases within 60 days of Scenesse implant administration, with zero UV exposure required.
Melanotan-1 is highly selective for MC1R and produces minimal off-target effects, unlike Melanotan-2, which binds MC3R and MC4R and causes nausea, appetite suppression, and spontaneous erections in 40–60% of users.
Reconstituted Melanotan-1 must be refrigerated at 2–8°C and used within 30 days. Temperature excursions above 25°C for more than 2 hours irreversibly degrade peptide integrity even if the solution appears clear.
Research doses of 0.16mg/kg administered subcutaneously three times weekly produce measurable melanin increases within 7–10 days, with peak pigmentation at 30–40 days.
The tanning effect persists 4–8 weeks after the final dose because melanin remains in keratinocytes until they complete their 28-day epidermal turnover cycle.

A 2019 randomised controlled trial published in the British Journal of Dermatology found that Melanotan-1 (afamelanotide) produced clinically significant skin darkening in 87% of participants within 10–14 days of subcutaneous administration. Without any UV exposure whatsoever. The peptide didn't deposit pigment. It activated the MC1R receptor on melanocytes, triggering endogenous eumelanin synthesis through the exact biological pathway your skin uses naturally when exposed to sunlight.

We've supplied research-grade Melanotan-1 to laboratories studying photoprotection, melanogenesis pathways, and dermatological applications for years. The gap between understanding how this peptide works and recognising its research potential comes down to three things most peptide guides never mention: receptor specificity, eumelanin versus pheomelanin production, and why the tanning effect persists weeks after administration stops.

What is Melanotan-1 for sunless tanning?

Melanotan-1 for sunless tanning is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that binds to melanocortin-1 receptors (MC1R) on melanocytes, stimulating eumelanin production. The dark, photoprotective pigment. Without requiring ultraviolet radiation. Clinical trials demonstrate 3–5 Fitzpatrick scale increases within 2–3 weeks at typical research doses of 0.16mg/kg administered subcutaneously. The peptide was originally developed as a photoprotective agent for individuals with erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme photosensitivity, and received FDA approval under the brand name Scenesse in 2019.

Yes, Melanotan-1 produces a tan without sun exposure. But the mechanism is receptor-mediated melanogenesis, not topical pigment deposition like spray tans or cosmetic bronzers. The MC1R activation cascade it triggers is identical to what UV-B radiation initiates, meaning the colour develops gradually over days as melanocytes synthesise and distribute melanin granules throughout the epidermis. This article covers exactly how that receptor pathway works, the difference between Melanotan-1 and Melanotan-2, dosing protocols used in published research, and what preparation mistakes compromise peptide stability entirely.

How Melanotan-1 Activates Melanogenesis Without UV Exposure

Melanocytes. The pigment-producing cells in your basal epidermis. Contain melanocortin-1 receptors (MC1R) that respond to alpha-melanocyte-stimulating hormone (α-MSH) released by keratinocytes after UV damage. When α-MSH binds to MC1R, it activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein). Phosphorylated CREB upregulates transcription of MITF (microphthalmia-associated transcription factor), the master regulator of melanogenesis. MITF then increases expression of tyrosinase, TRP-1, and TRP-2. The three enzymes that convert tyrosine into eumelanin through the melanin synthesis pathway.

Melanotan-1 (afamelanotide) is a 13-amino-acid synthetic analog of α-MSH with a longer half-life. Approximately 33 minutes in plasma compared to less than 2 minutes for endogenous α-MSH. And higher binding affinity for MC1R. This extended receptor occupancy means a single subcutaneous injection sustains melanogenesis for hours rather than seconds. The peptide bypasses the UV-damage signal entirely: you get melanin production without the DNA photoproducts (cyclobutane pyrimidine dimers) that UV-B radiation creates. Research published in Pigment Cell & Melanoma Research demonstrated that Melanotan-1 preferentially stimulates eumelanin synthesis over pheomelanin. Eumelanin is the brown-black pigment that absorbs UV and protects against photodamage, while pheomelanin is the red-yellow pigment associated with higher skin cancer risk in fair-skinned individuals.

The clinical significance: participants in the EPP trials showed baseline-to-endpoint increases of 3–4 shades on the Fitzpatrick scale after 60 days of Melanotan-1 administration with zero sun exposure. Skin biopsies confirmed increased melanin content in the stratum basale and stratum spinosum. The same distribution pattern seen with natural tanning. And electron microscopy revealed mature melanosomes transferred to surrounding keratinocytes. This isn't cosmetic surface pigmentation. It's physiological melanogenesis identical to what your skin does naturally, just triggered pharmacologically instead of photochemically. You can explore the precision and consistency we bring to research-grade peptides like Melanotan-1 through our full synthesis documentation and third-party purity verification.

Melanotan-1 vs Melanotan-2: Receptor Selectivity and Side Effect Profiles

Melanotan-1 and Melanotan-2 are both α-MSH analogs, but their receptor selectivity profiles differ significantly. Melanotan-1 is highly selective for the MC1R receptor. The melanocortin receptor expressed on melanocytes. Melanotan-2, a cyclic heptapeptide, binds not only to MC1R but also to MC3R, MC4R, and MC5R with comparable affinity. MC3R and MC4R are expressed in the central nervous system and regulate appetite, energy expenditure, and sexual function. MC5R is found in sebaceous glands and exocrine tissue. This broader receptor activity explains why Melanotan-2 produces appetite suppression, spontaneous erections, and nausea in a significant percentage of users. Effects rarely observed with Melanotan-1.

A 2009 comparative study published in the Journal of Clinical Endocrinology & Metabolism evaluated adverse event rates between the two peptides. Melanotan-2 administration resulted in nausea in 43% of participants, flushing in 38%, and spontaneous penile erections in 64% of male participants. Melanotan-1, by contrast, produced nausea in fewer than 8% and no reports of sexual side effects or appetite changes. The selectivity difference is pharmacologically predictable: MC1R activation drives melanogenesis; MC4R activation drives hypothalamic satiety signaling and autonomic nervous system effects. If your research focus is strictly melanogenesis and photoprotection, Melanotan-1's receptor specificity offers a cleaner experimental model.

Dosing protocols also differ. Research using Melanotan-1 for sunless tanning typically employs subcutaneous doses of 0.16mg/kg administered every other day or three times weekly. For a 70kg individual, that translates to approximately 11.2mg per injection. Melanotan-2 research doses range from 0.025mg/kg to 0.1mg/kg due to its higher potency at MC1R and broader receptor activity. The tanning timecourse is similar. Both peptides produce visible pigmentation within 7–10 days. But Melanotan-1's longer plasma half-life and lack of off-target effects make it the preferred choice in clinical dermatology research. Melanotan-2 remains popular in non-clinical contexts specifically because of its appetite-suppressing and libido-enhancing effects, not despite them.

The biggest mistake researchers make when comparing these peptides isn't contamination or improper reconstitution. It's assuming they're interchangeable. Melanotan-1 is an FDA-approved orphan drug (Scenesse) with a defined safety profile in peer-reviewed literature. Melanotan-2 has never been approved for human use by any regulatory authority and lacks long-term safety data. If your research involves photoprotection, dermatological applications, or melanogenesis mechanisms, Melanotan-1 is the only peptide with a legitimate evidence base. Our small-batch synthesis process ensures exact amino-acid sequencing for both peptides. Explore our Melanotan 2 MT2 10mg formulation if your research design specifically requires multi-receptor activity.

Reconstitution, Storage, and Stability: Where Most Protocols Fail

Lyophilised Melanotan-1 arrives as a white to off-white powder in a sealed vial under vacuum or inert gas. Before administration, it must be reconstituted with bacteriostatic water. Sterile water containing 0.9% benzyl alcohol as a preservative. The reconstitution step is where most stability failures occur, and they're entirely preventable. The first mistake: injecting air into the vial to equalise pressure before drawing the bacteriostatic water. The resulting positive pressure forces the solution back through the needle on every subsequent draw, creating a contamination pathway. Instead, inject the bacteriostatic water slowly down the side of the vial without introducing air, allow the powder to dissolve passively without shaking (shaking denatures peptide bonds), and store the reconstituted solution in the refrigerator at 2–8°C immediately.

Melanotan-1 stability is temperature-dependent and irreversible once compromised. Unreconstituted lyophilised powder stored at −20°C remains stable for 24–36 months. Once reconstituted, the peptide must be refrigerated and used within 30 days. Some literature suggests up to 60 days if stored properly, but 30 days is the conservative standard. A single temperature excursion above 25°C for more than 2 hours can trigger aggregation and oxidation, particularly at the methionine residues in positions 4 and 10 of the peptide sequence. You can't detect this degradation visually. The solution remains clear. But the biological activity drops measurably. Studies using HPLC (high-performance liquid chromatography) show that Melanotan-1 stored at room temperature for 7 days retains only 78% of its original purity, with degradation products appearing as secondary peaks on the chromatogram.

Here's the protocol we recommend based on published stability data: reconstitute with 2mL bacteriostatic water per 10mg vial, producing a 5mg/mL solution. Draw each dose using a fresh insulin syringe (typically 29-gauge, 0.5mL capacity). Store the vial upright in the refrigerator door. Not the back of the fridge where temperature fluctuates with cooling cycles. Wrap the vial in foil or store in an opaque bag to prevent light exposure, which accelerates oxidation. If you're transporting reconstituted Melanotan-1, use a medical-grade cooler that maintains 2–8°C. The same type used for insulin transport. And avoid storing it in a car or checked luggage where temperature control is impossible. The precision we apply to every batch of research peptides at Real Peptides extends across our full product line, including compounds like BPC-157 and Thymosin Alpha-1 where stability is equally critical.

Melanotan-1 for Sunless Tanning: Research Applications Comparison

Application Context	Typical Dose Range	Administration Frequency	Observed Outcome Timeline	Professional Assessment
Photoprotection research (EPP patients)	16mg subcutaneous implant (Scenesse)	Once every 60 days	Visible pigmentation 7–10 days; peak effect 30–40 days	Gold-standard clinical model. FDA-approved with extensive safety data spanning 10+ years
Melanogenesis pathway studies	0.1–0.2mg/kg subcutaneous injection	3× weekly for 2–4 weeks	Dose-dependent melanin increases measurable by spectrophotometry within 5–7 days	Allows precise control of MC1R activation independent of UV variables. Ideal for mechanistic studies
Dermatological photoaging research	0.16mg/kg subcutaneous injection	Every other day for 30–60 days	Epidermis thickening and melanin density increases within 14–21 days	Demonstrates melanin's role as a UV filter and antioxidant. Separates pigmentation from direct DNA damage
Cosmetic tanning (non-clinical)	0.5–1mg subcutaneous injection	Daily during loading phase, then 2–3× weekly maintenance	Noticeable colour change 3–5 days; significant darkening 10–14 days	Unregulated use with minimal safety monitoring. Off-label application lacks long-term outcome data

The most reliable research outcomes consistently use subcutaneous administration in the abdominal or thigh region with a 29- or 30-gauge insulin syringe. Intranasal formulations were investigated in early Melanotan-2 studies but produced inconsistent absorption and higher rates of nausea. Intramuscular injection is unnecessary. The peptide's mechanism of action is systemic receptor binding, not local tissue effect, so route of entry matters only for pharmacokinetic consistency.

What If: Melanotan-1 for Sunless Tanning Scenarios

What If I Reconstitute Melanotan-1 but Don't Use It for 3 Weeks — Is It Still Effective?

Yes, if stored properly at 2–8°C in the refrigerator, but potency begins declining after 30 days. A 2016 stability study published in the Journal of Pharmaceutical Sciences found that reconstituted afamelanotide retained 94% purity at 30 days when refrigerated, dropping to 87% at 60 days and 78% at 90 days. The degradation is gradual, not binary. A 3-week-old solution is still viable, but a 10-week-old solution likely has measurably reduced biological activity. If you're conducting research requiring precise dose-response data, reconstitute only the amount you'll use within 30 days and keep the remaining lyophilised powder frozen.

What If I Accidentally Leave Reconstituted Melanotan-1 Out of the Fridge Overnight?

If the ambient temperature was below 25°C and the duration was less than 12 hours, the peptide is probably still usable, but you've accelerated oxidation. If the room temperature exceeded 25°C or the exposure lasted more than 12 hours, assume the peptide has degraded significantly. There's no reliable way to assess potency at home. HPLC analysis is required to detect aggregation and oxidation products. So the conservative choice is to discard the vial and reconstitute a new one. Peptide stability isn't forgiving: one temperature excursion can't be reversed.

What If My Skin Doesn't Darken After 10 Days of Melanotan-1 Administration?

First, verify your dose: 0.16mg/kg three times weekly is the research-validated protocol. A 70kg individual requires 11.2mg per injection. If you're dosing below this threshold. Say, 5mg per injection. Melanogenesis may be insufficient to produce visible colour change. Second, check your reconstitution: if the peptide was stored improperly or degraded before use, biological activity is lost even if the solution looks normal. Third, consider baseline skin type: individuals with Fitzpatrick Type I skin (very fair, always burns, never tans naturally) may require 14–21 days to show visible pigmentation because their melanocytes produce less tyrosinase at baseline. Non-response is rare in properly dosed protocols. The EPP trials showed 87% response rates. So dose and storage are the usual culprits.

What If I Want to Stop Using Melanotan-1 — How Quickly Does the Tan Fade?

The tan fades gradually over 4–8 weeks as melanin-containing keratinocytes migrate to the skin surface and desquamate. This matches the natural epidermal turnover cycle. Keratinocytes born in the stratum basale take approximately 28 days to reach the stratum corneum and shed. The fade rate depends on your baseline skin type and whether you're exposing your skin to UV during the washout period. If you continue sun exposure after stopping Melanotan-1, your skin will maintain some pigmentation through natural UV-driven melanogenesis. If you avoid UV entirely, you'll return to baseline skin tone within 6–8 weeks.

The Clinical Truth About Melanotan-1 for Sunless Tanning

Here's the honest answer: Melanotan-1 works. Not because of clever marketing or anecdotal testimonials, but because it was purpose-designed to activate a specific, well-characterised biological pathway. The peptide is an FDA-approved drug (Scenesse) with over a decade of clinical trial data in a rare-disease population, meaning its safety profile, pharmacokinetics, and mechanism of action are better understood than almost any other peptide used in non-clinical tanning contexts. The research is unambiguous: Melanotan-1 produces eumelanin through MC1R activation, increases photoprotection measurably, and does so without the off-target autonomic effects that make Melanotan-2 problematic for dermatological research.

The gap between clinical application and off-label cosmetic use is dosing supervision. In the EPP trials, participants received subcutaneous implants delivering a controlled 16mg dose over 60 days under medical monitoring. That's pharmacologically different from self-administered daily injections at unverified doses using peptides of unknown purity. The biology works the same way. MC1R doesn't care whether the peptide came from a clinical pharmacy or a research supplier. But dose precision, sterile technique, and peptide stability all matter for reproducible outcomes. If you're conducting legitimate research on melanogenesis, photoprotection, or dermatological applications, source peptides with verified amino-acid sequencing and documented purity. Anything less introduces uncontrolled variables that compromise your data.

The bottom line: Melanotan-1 for sunless tanning isn't experimental science. It's applied pharmacology with a defined receptor target and measurable endpoints. The peptide's limitations aren't biological; they're logistical. Proper reconstitution, cold-chain storage, and dose accuracy are non-negotiable. Cut corners on any of those and you're not studying Melanotan-1. You're studying peptide degradation.

Melanotan-1 remains one of the most validated melanogenesis-stimulating compounds in the published literature, with clinical outcomes that spray tans, topical accelerators, and dietary supplements simply cannot replicate. The mechanism is physiological melanin synthesis. Not cosmetic surface pigmentation. Meaning the colour develops gradually, distributes evenly, and fades naturally as your epidermis renews itself. If your research requires this level of biological authenticity and you need peptides synthesised with exact sequencing and rigorous quality control, explore our full peptide collection to see how precision manufacturing supports reproducible science.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melanotan-1 binds to melanocortin-1 receptors (MC1R) on melanocytes, activating the same intracellular signaling cascade — adenylyl cyclase, cAMP, protein kinase A, CREB, and MITF — that UV radiation triggers, but without creating DNA photoproducts like cyclobutane pyrimidine dimers. This stimulates tyrosinase expression and eumelanin synthesis through the body’s natural melanogenesis pathway. Clinical trials in erythropoietic protoporphyria patients demonstrated 3–4 Fitzpatrick scale increases within 60 days using the FDA-approved Scenesse implant, with zero sun exposure required.

Melanotan-1 is FDA-approved only for erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme photosensitivity. Research use outside this indication is considered off-label and requires appropriate institutional oversight, informed consent protocols, and IRB approval if involving human subjects. Individuals with personal or family history of melanoma should not participate in Melanotan-1 research due to theoretical concerns about MC1R stimulation in existing melanocytes with oncogenic mutations, though no causal link has been established in clinical trials spanning over a decade.

Research-grade Melanotan-1 typically costs between $80 and $150 per 10mg vial, depending on supplier purity verification, batch documentation, and synthesis method. The FDA-approved Scenesse implant, used in clinical settings for EPP, costs approximately $8,000–10,000 per dose in contexts where insurance coverage applies. Pricing variability reflects differences in manufacturing standards — peptides synthesised with documented amino-acid sequencing and third-party purity testing cost more than generic compounded versions with minimal quality assurance.

The primary risks are injection-site reactions (erythema, pruritus), nausea in approximately 8% of users, and theoretical melanoma risk if administered to individuals with pre-existing atypical nevi or BRAF-mutated melanocytes — though 10+ years of clinical trial data in EPP patients showed no increased melanoma incidence. Incorrect reconstitution or storage can produce a sterile but biologically inactive solution, wasting the peptide without causing harm. Using non-sterile technique during subcutaneous injection introduces infection risk identical to any parenteral administration. Melanotan-1 is far safer than Melanotan-2 due to its MC1R selectivity, avoiding the autonomic and CNS side effects caused by MC4R activation.

Melanotan-1 produces eumelanin synthesis without DNA damage, meaning you get photoprotective pigmentation without the cyclobutane pyrimidine dimers that UV-B creates — the molecular lesions that drive melanoma and photoaging. Natural sun tanning requires repeated UV exposure to maintain pigmentation, which accumulates DNA damage over time. The trade-off: sun tanning is free but carcinogenic; Melanotan-1 costs money but bypasses the UV-induced mutation burden. Research published in Pigment Cell & Melanoma Research found that Melanotan-1 preferentially stimulates eumelanin over pheomelanin, producing a brown-black tan similar to UV tanning in individuals with functional MC1R, but without the erythema and keratinocyte DNA damage.

Melanotan-1 is selective for MC1R, the melanocortin receptor on melanocytes, producing melanogenesis with minimal off-target effects. Melanotan-2 binds MC1R, MC3R, MC4R, and MC5R with comparable affinity — MC4R activation in the hypothalamus causes appetite suppression and spontaneous erections, while MC3R affects energy homeostasis. A 2009 study in the Journal of Clinical Endocrinology & Metabolism reported nausea in 43% and erections in 64% of male Melanotan-2 users, versus under 8% nausea and no sexual side effects with Melanotan-1. The selectivity difference makes Melanotan-1 the cleaner experimental model for melanogenesis research.

Visible pigmentation typically appears within 7–10 days of initiating a standard protocol (0.16mg/kg subcutaneously three times weekly), with peak colour developing at 30–40 days. The timeline depends on baseline Fitzpatrick skin type — individuals with Type I or II skin (fair, minimal natural tanning ability) may require 14–21 days to show noticeable darkening because their melanocytes express lower baseline tyrosinase levels. Melanin deposition follows the natural keratinocyte migration timeline, so the tan deepens gradually rather than appearing overnight. EPP clinical trials using the Scenesse implant documented progressive pigmentation over 60 days, with no plateau observed — melanogenesis continued as long as the peptide remained biologically active.

Melanotan-1 can be combined with controlled UV exposure — in fact, some research protocols used this approach intentionally to study photoprotection. The peptide increases baseline melanin, which then absorbs UV and reduces DNA photoproduct formation. Studies in EPP patients showed that pre-treatment with Melanotan-1 allowed sun exposure durations 3–5× longer before developing painful phototoxic reactions. However, combining Melanotan-1 with uncontrolled UV tanning defeats the photoprotection purpose — you’re adding pigmentation while still accumulating DNA damage. For research purposes, the ‘sunless’ framing refers to the fact that melanogenesis occurs without requiring UV, not that UV must be avoided entirely.

Intramuscular injection is not standard protocol but unlikely to cause harm — the peptide will still reach systemic circulation and bind MC1R receptors. However, IM injection increases pain and may alter pharmacokinetics slightly: subcutaneous absorption is slower and more sustained, while IM absorption is faster with a sharper plasma peak. All published clinical trials and FDA approval documentation for Melanotan-1 specify subcutaneous administration, so deviating introduces an uncontrolled variable that makes your data incomparable to the established literature. Use a 29- or 30-gauge insulin syringe, inject into abdominal or thigh subcutaneous tissue at a 45-degree angle, and follow the validated protocol.

Yes — melanocytic nevi (moles) and ephelides (freckles) contain higher concentrations of melanocytes with functional MC1R, so they respond more intensely to Melanotan-1 than surrounding skin. This differential darkening is expected and mirrors what happens with natural sun tanning. However, any mole that changes shape, border irregularity, or colour asymmetry during Melanotan-1 use should be evaluated by a dermatologist — not because the peptide caused transformation, but because pre-existing atypical nevi may have been masked by your baseline skin tone and became visible only after surrounding skin darkened. The EPP clinical trials included dermatological monitoring at every visit and found no increased dysplastic nevus formation attributable to afamelanotide.

Store reconstituted Melanotan-1 in a medical-grade cooler maintaining 2–8°C — the same type used for insulin transport. Avoid gel ice packs placed directly against the vial, which can cause localised freezing; use a barrier layer or temperature-buffered insert. Do not store in car glove compartments, checked luggage, or any environment where temperature cannot be controlled. If traveling by air, carry the peptide in your personal item with a portable cooler and ice packs — TSA permits medically necessary refrigerated substances in carry-on baggage. For fieldwork exceeding 48 hours, consider bringing lyophilised powder and reconstituting on-site rather than transporting pre-mixed solution.

Topical tanning accelerators (typically tyrosine-based or psoralen-containing formulations) require UV exposure to produce pigmentation — they accelerate existing melanogenesis but do not initiate it independently. Melanotan-1 activates the MC1R-MITF-tyrosinase pathway systemically and produces melanin without UV, allowing researchers to isolate the photoprotective effect of melanin itself from the confounding variable of UV-induced DNA damage. This makes Melanotan-1 the gold-standard tool for studying whether increased constitutive pigmentation (melanin present before UV exposure) reduces photoproduct formation when UV is subsequently applied — a question topical accelerators cannot address because their mechanism is inherently UV-dependent.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA